Cognate BioServices, Inc. was a privately-held contract development and manufacturing organization (CDMO) developing cell-based products and therapies
Cognate was a privately-held outsourced cell and gene therapy CDMO in a market driven by biopharmaceutical companies’ continued investment in CAR-T, cell therapy, and gene therapy programs. Cognate’s core offerings were focused on immunotherapy, cell therapy, gene therapy, viral vectors, and DNA plasmids.
Cognate had significant experience in autologous and allogeneic cell therapies and other advanced cell therapies such as CAR-T, NK cell, TIL, MIL, and other cellular immunotherapy products.
Cobra, its wholly owned subsidiary, had expertise, from development to fill-finish, in viral vectors including AAV and lentivirus, DNA plasmids, microbiota, and specialized proteins, with GMP approved facilities in both Sweden and the UK.
Cognate and Cobra provided a combination of services to companies across various points of clinical and commercial development specializing in mid to late stage clinical trials. The companies supported their clients through product scale-up through commercial manufacturing. Cognate and Cobra’s combination of manufacturing and clinical expertise resulted in an effective operating history, suited to continue its strong growth, high quality manufacturing processes, and excellent customer service.
Charles River Laboratories acquired Cognate and Cobra in March 2021.